Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBIT (2016 - 2025)

Historic EBIT for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Utah Medical Products' EBIT fell 2189.65% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 1860.62%. This contributed to the annual value of $2.8 million for FY2024, which is 1909.63% up from last year.
  • As of Q3 2025, Utah Medical Products' EBIT stood at $2.6 million, which was down 2189.65% from $3.2 million recorded in Q2 2025.
  • Utah Medical Products' 5-year EBIT high stood at $5.1 million for Q3 2022, and its period low was $2.6 million during Q3 2025.
  • Its 5-year average for EBIT is $4.1 million, with a median of $4.0 million in 2023.
  • In the last 5 years, Utah Medical Products' EBIT surged by 14102.18% in 2021 and then plummeted by 2570.99% in 2024.
  • Quarter analysis of 5 years shows Utah Medical Products' EBIT stood at $5.1 million in 2021, then dropped by 1.17% to $5.1 million in 2022, then dropped by 22.21% to $3.9 million in 2023, then fell by 25.71% to $2.9 million in 2024, then decreased by 10.89% to $2.6 million in 2025.
  • Its EBIT stands at $2.6 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.2 million for Q1 2025.